Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combinations
AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.
AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.
AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.
AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.